Complete financial analysis of Pyxis Oncology, Inc. (PYXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pyxis Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Barnes & Noble Education, Inc. (BNED) Income Statement Analysis – Financial Results
- PB Financial Corporation (PBNC) Income Statement Analysis – Financial Results
- Omaxe Limited (OMAXE.BO) Income Statement Analysis – Financial Results
- Comstock Resources, Inc. (CRK) Income Statement Analysis – Financial Results
- JoulWatt Technology (688141.SS) Income Statement Analysis – Financial Results
Pyxis Oncology, Inc. (PYXS)
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.84M | 1.25M | 444.00K | 0.00 |
| Gross Profit | -2.00M | -1.84M | -1.25M | -444.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.59M | 86.13M | 51.05M | 9.05M | 1.22M |
| General & Administrative | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 181.00K | 0.00 | 0.00 |
| Operating Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Cost & Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Interest Income | 6.63M | 2.76M | 23.00K | 66.00K | 107.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.00M | 1.84M | 1.25M | 444.00K | 2.88M |
| EBITDA | -78.49M | -122.77M | -69.07M | -12.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -82.20M | -123.48M | -69.72M | -12.89M | -2.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.41M | 2.76M | -6.26M | 66.00K | 107.00K |
| Income Before Tax | -73.79M | -120.72M | -75.98M | -12.83M | -2.77M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.76M | 5.56M | -66.00K | -107.00K |
| Net Income | -73.79M | -117.95M | -81.54M | -12.76M | -2.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| EPS Diluted | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| Weighted Avg Shares Out | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
| Weighted Avg Shares Out (Dil) | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
Moment Of Truth Approaches For Pyxis Oncology
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
Source: https://incomestatements.info
Category: Stock Reports